aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
November 10 2020 - 7:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that it has identified
receptor targets for two tRNA synthetases from its pipeline. The
receptor targets may have utility in the development of new
therapeutics to treat cancer and fibrosis. The company expects to
present findings from this research at a scientific conference in
the future.
Human tRNA synthetases play a role in
extracellular responses in certain disease states, including
cellular stress and tissue homeostasis. Identifying target
receptors for an extracellular tRNA synthetase helps inform
discovery and development activities by providing additional focus
towards relevant disease pathways and potential therapeutic
applications.
“We are pleased to advance our knowledge of this
newly discovered area of biology by identifying these receptor
targets. This represents a key milestone in our drug discovery
efforts,” said Sanjay S. Shukla, M.D., M.S., President and Chief
Executive Officer of aTyr. “The process by which we identified
these receptor targets presents a novel approach to extracellular
tRNA synthetase drug discovery and development and further
validates our biology platform as one that can generate new
potential drug targets. We look forward to exploring the pathways
of these receptor targets and how they relate to altered disease
states, which may contribute to the development of new therapeutic
approaches in the areas of oncology and fibrosis, including
potential new protein and antibody therapies.”
The discovery work was completed as part of a
research collaboration with CSL Behring, a global biotherapeutics
leader specializing in immunology, hematology and other rare and
serious medical conditions.
About
aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding potential further research and
development activities related to, and potential utility of, the
newly-identified receptor targets, the potential therapeutic
benefits and applications of our current and future product
candidates, timelines and plans with respect to certain development
activities, and certain development goals. These forward-looking
statements also reflect our current views about our plans,
intentions, expectations, strategies and prospects, which are based
on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions,
expectations, strategies and prospects, as reflected in or
suggested by these forward-looking statements, are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. All forward-looking
statements are based on estimates and assumptions by our management
that, although we believe to be reasonable, are inherently
uncertain. Furthermore, actual results may differ materially from
those described in these forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, uncertainty regarding the
COVID-19 pandemic, risks associated with the discovery, development
and regulation of our product candidates, the risk that we or our
partners may cease or delay preclinical or clinical development
activities for any of our existing or future product candidates for
a variety of reasons (including difficulties or delays in patient
enrollment in planned clinical trials), the possibility that
existing collaborations could be terminated early, and the risk
that we may not be able to raise the additional funding required
for our business and product development plans, as well as those
risks set forth in our most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and in our other SEC filings. Except
as required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: |
Ashlee Dunston |
Director,
Investor Relations and Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024